Inhalation Sciences Q1’22: Eventful Start to 2022 - Redeye

Redeye comments on ISAB’s Q1’22 report. The company has seen a continued high interest for its IRS business during the first quarter and with a pending FDA approval for its white paper proposal submitted in January, the company has an interesting period ahead.

Länk till analysen i sin helhet: https://www.redeye.se/research/843047/inhalation-sciences-q122-eventful-start-to-2022?utm_source=finwire&utm_medium=RSS